培美曲塞二线治疗晚期非小细胞肺癌临床观察  

Study of pemetrexed as second-line therapy for patients with advanced nonsqamous non-small-cell Lung cancer

作　　者：龙建林[1] 易全会 任章霞[1] 杨宁[1] 

机构地区：[1]广安市人民医院肿瘤科,四川广安638000

出　　处：《西部医学》2012年第1期40-42,共3页Medical Journal of West China

摘　　要：目的观察培美曲塞二线治疗晚期非鳞癌非小细胞肺癌(NSCLC)的客观有效率(RR)、中位无进展时间(PFS)及安全性。方法 21例经过一线三代含铂化疗方案失败的晚期非鳞癌NSCLC患者,接受培美曲塞单药二线治疗,主要观察指标是RR、中位PFS及安全性。结果 21例患者均可接受疗效和生存评价。其中部分缓解(Partial re-sponse,PR)3例(14.3%)、稳定(Stable disease,SD)12例(57.1%)、进展(Progression disease,PD)6例(28.6%),没有患者达到完全缓解(Complete response,CR)。RR为14.3%,临床获益率(Clinical benefit rate,CBR)71.4%,中位PFS为4.1个月。没有Ⅲ～Ⅳ度的血液学毒性和神经系统毒性。结论培美曲塞单药二线治疗能够提高一线三代含铂化疗失败的晚期非鳞癌NSCLC的RR、中位PFS,耐受性更好。Objetive To observe the response rate,median progression-free survival and safety of pemetrexed as second line therapy for patients with advanced nonsqamous non-small-cell lung cancer.Methods 21 non-sqamouse NSCLC patients failed in third generation platin-based doublet regimens received pemetraxed treatment alone.The endpoints were RR,median PFS and safety.Results All patients could be evaluated of response and survival.Of those 21 patients,there were 3 patients with PR,12 with SD and 6 with PD.The RR was 14.3%,CBR was 71.4% and median PFS was 4.1 months.There were not Ⅲ～Ⅳ grade toxicity of hematologic and neurologyic system.Conclusion Pemetrexed alone as second line therapy for patients with non-sqamous NSCLC failed in first line platin-based doublet could improve the RR,median PFS.The toxicities were more tolerable.

关 键 词：培美曲塞 二线治疗 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]